Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 7:33 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 51 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: SOC Antibiotics Clear all
Completed Phase 2 Interventional

Liposomal Amikacin for Inhalation (LAI) in the Treatment of Mycobacterium Abscessus Lung Disease

NCT03038178
View directory record Official record
Conditions
Mycobacterium Infections, Nontuberculous, Mycobacteria, Atypical
Interventions
LAI plus multi-drug regimen
Drug
Lead sponsor
Kevin Winthrop
Other
Eligibility
12 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
2
States / cities
Portland, Oregon • Tyler, Texas
Source: ClinicalTrials.gov public record
Updated Mar 4, 2020 · Synced Oct 25, 2026, 7:33 PM EDT
Not listed Not applicable Interventional

Assessment of the Effects on the Skin Microbiome of Amending an Over-the-counter Eczema Product With Activated Oil (AO)

NCT05413395
View directory record Official record
Conditions
Eczema
Interventions
topical colloidal oatmeal formulation with a modified plant oil, topical colloidal oatmeal formulation
Other
Lead sponsor
GlycosBio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 5, 2022 · Synced Oct 25, 2026, 7:33 PM EDT
Recruiting Phase 2 Interventional

A Randomized Controlled Phase II Trial of STIMULAN VG vs Standard of Care (SoC) for the Treatment of Osteomyelitis Associated With Stage IV Pressure Ulcers.

NCT06283979
View directory record Official record
Conditions
Pressure Ulcer, Stage IV, Osteomyelitis
Interventions
STIMULAN VG, Standard of Care
Combination Product · Procedure
Lead sponsor
Biocomposites Ltd
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
9
States / cities
Phoenix, Arizona • Chicago, Illinois • Detroit, Michigan + 6 more
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 25, 2026, 7:33 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Study to Assess Wound Healing Efficacies of Different Clean, Treat, and Protect Wound Care Regimens Compared to Standard of Care and Untreated

NCT05045183
View directory record Official record
Conditions
Wound Healing
Interventions
SoC Adhesive Bandage, Antibiotic Ointment, Antiseptic Wash, Hydrocolloid Pad
Device · Drug
Lead sponsor
Johnson & Johnson Consumer Inc. (J&JCI)
Industry
Eligibility
25 Years to 55 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Richardson, Texas
Source: ClinicalTrials.gov public record
Updated Mar 25, 2025 · Synced Oct 25, 2026, 7:33 PM EDT
Recruiting Phase 2 Interventional

A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation

NCT06859424
View directory record Official record
Conditions
AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL), Acute Leukemia (Category), MDS (Myelodysplastic Syndrome), CML (Chronic Myelogenous Leukemia), CLL (Chronic Lymphocytic Leukemia), Prolymphocyctic Leukemia, Chronic Myelomonocytic Leukemia (CMML), Myeloproliferative Neoplasm (MPN), Lymphoma, Myelofibrosis
Interventions
Conditioning Regimen A, Conditioning Regimen B, Conditioning Regimen C, Conditioning Regimen D, Conditioning Regimen E, Hematopoietic Cell Transplantation, PTCy (50 mg/kg D3, D4), PTCy (25 mg/kg D3, D4), Post-transplant Tacrolimus, Post-transplant Mycophenolate mofetil, Post-transplant Abatacept, Post-transplant Ruxolitinib, Supportive Care: Growth Factors, Supportive Care: Blood Products, Supportive Care: Infection Prophylaxis, Supportive Care: Intravenous immune globulin (IVIG), Supportive Care: Seizure prophylaxis, Supportive Care: Monitoring and management of CRS, Supportive Care: Prophylaxis against infections, Supportive Care: Prophylaxis against infections, Supportive Care: Lipid elevations, Study treatment compliance, Prohibited Concomitant Therapy, Permitted Concomitant Therapy
Drug · Procedure · Other
Lead sponsor
Center for International Blood and Marrow Transplant Research
Network
Eligibility
18 Years to 66 Years
Enrollment
358 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
13
States / cities
Birmingham, Alabama • Duarte, California • Palo Alto, California + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Oct 25, 2026, 7:33 PM EDT
Not listed Not applicable Interventional

Safety Study of a Novel Wearable Phototherapy System for the Management of Acute Burn Wounds

NCT03948360
View directory record Official record
Conditions
Burn Wound
Interventions
Low-Irradiance Monochromatic Biostimulation (LIMB) Device, Standard of Care
Device · Other
Lead sponsor
Rogers Sciences Inc.
Industry
Eligibility
Up to 21 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 13, 2019 · Synced Oct 25, 2026, 7:33 PM EDT
Completed Not applicable Interventional

Complex And Simple Appendicitis: REstrictive or Liberal Post-operative Antibiotic eXposure (CASA RELAX) - Atrium Health

NCT05746520
View directory record Official record
Conditions
Appendicitis Surgery
Interventions
Antibiotic
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
268 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 3, 2025 · Synced Oct 25, 2026, 7:33 PM EDT
Terminated Phase 3 Interventional

Evaluate the Safety and Efficacy of ON101 Cream for the Treatment of Chronic Diabetic Foot Ulcers

NCT04962139
View directory record Official record
Conditions
Chronic Diabetic Foot Ulcers
Interventions
ON101 Cream, Vehicle Cream
Drug · Other
Lead sponsor
Oneness Biotech Co., Ltd.
Industry
Eligibility
18 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
14
States / cities
Mesa, Arizona • Carlsbad, California • Castro Valley, California + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2025 · Synced Oct 25, 2026, 7:33 PM EDT
Completed Phase 4 Interventional Results available

Comparing Outcomes for Prontosan Versus Normal Saline for Negative Pressure Wound Therapy With Instillation

NCT01939145
View directory record Official record
Conditions
Wound Infection
Interventions
Normal saline, Prontosan
Drug · Device
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Dec 29, 2016 · Synced Oct 25, 2026, 7:33 PM EDT
Completed Phase 2 Interventional Results available

Study of Efficacy and Safety of MAS825 in Patients With COVID-19

NCT04382651
View directory record Official record
Conditions
COVID-19 Pneumonia, Impaired Respiratory Function
Interventions
MAS825, Placebo, Standard of Care (SoC)
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
21
States / cities
Chula Vista, California • Glendale, California • Irvine, California + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2022 · Synced Oct 25, 2026, 7:33 PM EDT
Terminated Phase 2 Interventional Results available

Dose Finding Study of Nemiralisib (GSK2269557) in Subjects With an Acute Moderate or Severe Exacerbation of Chronic Obstructive Pulmonary Disease (COPD)

NCT03345407
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Placebo ELLIPTA, Nemiralisib ELLIPTA 50 µg, Nemiralisib ELLIPTA 100 µg, Nemiralisib ELLIPTA 250 µg, Nemiralisib ELLIPTA 500 µg, Nemiralisib ELLIPTA 750 µg, Albuterol (Salbutamol) MDI or nebules, Standard of care therapy
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years to 80 Years
Enrollment
943 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
21
States / cities
Mobile, Alabama • Colorado Springs, Colorado • Daytona Beach, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2021 · Synced Oct 25, 2026, 7:33 PM EDT
Terminated Not applicable Interventional Results available

The Effect of Irrisept for Irrigation of Skin and Soft Tissue Infections (Irrisept USF Study)

NCT01076049
View directory record Official record
Conditions
Skin and Soft Tissue Infections, Abscess
Interventions
Standard of Care (SoC), Irrisept Delivery System
Device
Lead sponsor
Irrimax Corporation
Industry
Eligibility
18 Years to 80 Years
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Aug 23, 2021 · Synced Oct 25, 2026, 7:33 PM EDT
Terminated Phase 4 Interventional

Complex And Simple Appendicitis: REstrictive or Liberal Post-operative Antibiotic eXposure - UCSF

NCT05966454
View directory record Official record
Conditions
Appendicitis
Interventions
Multiple standard of care antibiotics for appendicitis, at physicians' discretion
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 25, 2026, 7:33 PM EDT
Suspended No phase listed Observational

Assessment of Patients With Acute Pouchitis Treated With Antibiotics

NCT05252273
View directory record Official record
Conditions
Pouchitis, Ulcerative Colitis
Interventions
Observational, No intervention
Other
Lead sponsor
Alimentiv Inc.
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
New York, New York • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 20, 2024 · Synced Oct 25, 2026, 7:33 PM EDT
Active, not recruiting Phase 2 Interventional

Controlled Trial of Omadacycline Randomized Treatment Given for Bone and Joint Infection

NCT05753215
View directory record Official record
Conditions
Bone Infection, Joint Infection, Bone and Joint Infection
Interventions
Omadacycline Pill, Standard of Care
Drug
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
18 Years to 85 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Oct 25, 2026, 7:33 PM EDT
Active, not recruiting Phase 2 Interventional

A Feasibility Trial to Investigate the Safety and Between-group Effect Size of STIMULAN VG and Standard of Care (SoC) in Participants With Diabetic Foot Osteomyelitis

NCT05539963
View directory record Official record
Conditions
Diabetic Foot Osteomyelitis
Interventions
STIMULAN VG, Systemic Antibiotics
Drug
Lead sponsor
Biocomposites Ltd
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
10
States / cities
Mesa, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2025 · Synced Oct 25, 2026, 7:33 PM EDT
Completed Not applicable Interventional Results available

Clinical Study to Compare Two Skin Substitute Categories for Their Effectiveness to Treat Diabetic Foot Ulcers

NCT06557122
View directory record Official record
Conditions
Diabetic Foot Ulcer
Interventions
SOC and Advanced Bioengineered Skin Substitute, SOC and Active Comparator
Device · Other
Lead sponsor
Encoll Corp
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
3
States / cities
Los Angeles, California • South Miami, Florida • Salem, Virginia
Source: ClinicalTrials.gov public record
Updated May 22, 2025 · Synced Oct 25, 2026, 7:33 PM EDT
Terminated Phase 1 Interventional Results available

Cefiderocol Concentrations in the Lungs of Hospitalized Patients With Bacterial Pneumonia

NCT03862040
View directory record Official record
Conditions
Bacterial Pneumonia
Interventions
Cefiderocol, Standard of Care Antibiotic
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
7
States / cities
Aurora, Colorado • Hartford, Connecticut • Jacksonville, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2020 · Synced Oct 25, 2026, 7:33 PM EDT
Completed Phase 2 Interventional Results available

Adjunctive Therapeutic Treatment With Human Monoclonal Antibody AR-105 (Aerucin®) in P. Aeruginosa Pneumonia

NCT03027609
View directory record Official record
Conditions
Pseudomonas Aeruginosa Pneumonia
Interventions
AR-105, Placebo
Drug
Lead sponsor
Aridis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
14
States / cities
Sacramento, California • San Diego, California • Jacksonville, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2022 · Synced Oct 25, 2026, 7:33 PM EDT
Enrolling by invitation Not applicable Interventional

Assessing Post-operative Outcomes After Children's Sistrunk Procedure With or Without a Drain

NCT07148895
View directory record Official record
Conditions
Thyroglossal Duct Cysts
Interventions
Post-surgical drain, No post-surgical drain
Procedure
Lead sponsor
University of Rochester
Other
Eligibility
3 Years to 17 Years
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
5
States / cities
Los Angeles, California • Hartford, Connecticut • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 25, 2026, 7:33 PM EDT
Completed Phase 2 Interventional Results available

Safety, Efficacy and Pharmacokinetics of CF-301 vs. Placebo in Addition to Antibacterial Therapy for Treatment of S. Aureus Bacteremia

NCT03163446
View directory record Official record
Conditions
Staphylococcus Aureus Bacteremia, Staphylococcus Aureus Endocarditis
Interventions
CF-301, Placebo
Biological · Drug
Lead sponsor
ContraFect
Industry
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
31
States / cities
Birmingham, Alabama • Sacramento, California • Sylmar, California + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2021 · Synced Oct 25, 2026, 7:33 PM EDT
Recruiting Not applicable Interventional

The Effect of Peri-Operative Adjunctive Probiotics on Immunological Markers in Cases of Prosthetic Joint Infection of the Hip and Knee

NCT06919913
View directory record Official record
Conditions
Prosthetic-joint Infection
Interventions
Culturelle Digestive Daily Probiotic Capsule
Dietary Supplement
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 90 Years
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Oct 25, 2026, 7:33 PM EDT
Not yet recruiting Phase 2 Interventional

Using TropoCells(R) Autologous Platelet-Rich Fibrin (PRF) to Treat Chronic Non-Healing Wounds

NCT07318792
View directory record Official record
Conditions
Wound Chronic Draining, Wound Closure
Interventions
Platelet-rich fibrin (PRF)
Device
Lead sponsor
Estar Medical dba Medical Technologies, LTD
Industry
Eligibility
18 Years to 80 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
3
States / cities
Bradenton, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Oct 25, 2026, 7:33 PM EDT
Terminated Not applicable Interventional

Clinical Assessment of Next Science Solution on Gustilo and Anderson Type II and IIIA or IIIB Tibial Fractures

NCT04906642
View directory record Official record
Conditions
Surgical Wound Infection
Interventions
Next Science, Standard of Care
Device · Other
Lead sponsor
Next Science TM
Industry
Eligibility
18 Years to 65 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
Birmingham, Alabama • Columbus, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 3, 2023 · Synced Oct 25, 2026, 7:33 PM EDT